Pegylation of Polypeptides

1. Technical Result Increase in therapeutic potential of the polypeptides. 2. Essence Compounds are disclosed having the general formula R1-X-R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or...

Full description

Saved in:
Bibliographic Details
Main Authors Evans, (US), Ronald, J, Thompson, (US), Robert C, Armes, (US), Lyman, G, Kohno, (US), Tadahiko, Brewer, (US), Michael, T
Format Patent
LanguageEnglish
Published 27.10.2003
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:1. Technical Result Increase in therapeutic potential of the polypeptides. 2. Essence Compounds are disclosed having the general formula R1-X-R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are interleukin-1 receptor antagonist, 30kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. The method for production of the mentioned compounds is provided. The pharmaceutical compositions and their use are provided. 3. Field of Application Medicine, in particular therapy.
Bibliography:Application Number: GE1992AP02637